The use of eplerenone in the treatment of postinfarction heart failure coexisting with potency disorders or gynecomastia – experience of Łódź center Case report

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Aug 12, 2017
Keywords:
aldosterone antagonists, eplerenone, adverse effects

Main Article Content

Marcin Barylski
Klinika Chorób Wewnętrznych i Rehabilitacji Kardiologicznej, Uniwersytet Medyczny w Łodzi

Abstract

Eplerenone is the latest selective aldosterone receptor antagonist. Compared with its nonselective precursor – spironolactone – has no adverse effects associated with the impact on receptors for sex hormones (gynecomastia and erectile dysfunction in men, menstrual disorders in women). The use of eplerenone is also associated with reduced (compared with spironolactone) frequency of other side effects (hyperkalemia, increased serum creatinine) and drug interactions. The results of clinical and experimental studies suggest that eplerenone is also superior to spironolactone due to pharmacodynamic properties other than selectivity to non-mineralocorticoid receptor.

Downloads

Download data is not yet available.

Article Details

How to Cite
Barylski , M. (2017). The use of eplerenone in the treatment of postinfarction heart failure coexisting with potency disorders or gynecomastia – experience of Łódź center. Cardiology in Practice, 11(2), 3-7. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1247
Issue
Vol 11 No 2 (2017)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Ponikowski P., Voors A.A., Anker S.D. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016; 18(8): 891-975.
2. Pitt B., Remme W., Zannad F. et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309-1321.
3. Zannad F., McMurray J.J., Krum H. et al.; EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 2011; 364: 11-21.
4. Kapłon-Cieślicka A., Filipiak K.J.: Eplerenon – co wiadomo o tym leku na początku 2009 roku? Choroby Serca i Naczyń 2009; 6: 26-36.
5. Garthwaite S.M., McMahon E.G.: The evolution of aldosterone antagonists. Mol. Cell. Endocrinol. 2004; 217: 27-31.
6. Szymański F.M., Filipiak K.J., Mamcarz A. et al.: Eplerenon w codziennej praktyce – aktualne miejsce w terapii i perspektywy stosowania w Polsce. Stanowisko ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Folia Cardiologica 2015; 10(4): 288-293.